Abstract: A recessed portion is formed at a frame member provided at a rear portion of a vehicle body and having a closed cross section extending in a vehicle longitudinal direction, wherein the recessed portion is configured such that a lower face of the frame member is recessed upwardly and a damper is inserted into and fixed to the recessed portion. Closed cross sections are formed inside the frame member at a position corresponding to the recessed portion. These closed cross sections are configured to branch off from the closed cross section outwardly and inwardly relative to the damper. A reinforcing member is fixed to the frame member and a wheel house inner at the position corresponding to the recessed portion such that a space is formed at a corner portion of these.

Abstract: A recessed portion is formed at a frame member provided at a rear portion of a vehicle body and having a closed cross section extending in a vehicle longitudinal direction such that a part of a lower face of the frame member is recessed upwardly, where a damper of a rear suspension is inserted and fixed. A front portion of the frame member is joined to a side sill extending in the vehicle longitudinal direction at a position offset outwardly in a vehicle width direction from the frame member. Branch-shaped closed cross sections branching off from the closed cross section inwardly and outwardly relative to the damper are formed at a position corresponding to the recessed portion of the frame member. A portion of the frame member located at the above-described position is wide outwardly.

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: A rear side frame comprises a front-side frame and a rear-side frame which is provided in back of the front-side frame and configured such that a strength thereof against compressing of an axial direction is lower than that of the front-side frame, a rear end portion of the front-side frame and a front end portion of the rear-side frame are overlapped, and another vehicle-body member is connected to an overlap portion where the rear end portion of the front-side frame and the front end portion of the rear-side frame are overlapped.

Abstract: In a rear vehicle-body structure of a vehicle provided with rear side frames, a first deformation promotion portion (recess portions) to promote inward deformation of the rear side frame is provided at each of both-side side face portions of the rear side frame, a second deformation promotion portion (opening portions) to promote outward deformation of the rear side frame is provided at a lower face portion of the rear side frame, and the first deformation promotion portion and the second deformation promotion portion are alternately arranged in an axial direction of the rear side frame.

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.

Abstract: An engine stop control device is provided for a vehicle that ensures a sufficient operation frequency of coast stop operation during travel on a congested road, thereby to improve practical fuel economy. The vehicle has an engine that is capable of being restarted. A controller is configured to stop the engine automatically when the vehicle, after experiencing a travel with a vehicle speed VSP exceeding a first threshold value, decreases the speed below a CS (coast stop) start vehicle speed. The controller is further configured to set a second threshold value below the first threshold value. The controller is further configured, after starting from an engine automatic stop due to the coast stop control and when the vehicle experiences travel exceeding the second threshold value without exceeding the first threshold value, to permit the automatic engine stop due to the coast stop control at least once.

Abstract: The present invention provides a compound of Formula I for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R1, X1, R7, R5, C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: A rear side frame comprises a front-side frame and a rear-side frame which is provided in back of the front-side frame and configured such that a strength thereof against compressing of an axial direction is lower than that of the front-side frame, a rear end portion of the front-side frame and a front end portion of the rear-side frame are overlapped, and another vehicle-body member is connected to an overlap portion where the rear end portion of the front-side frame and the front end portion of the rear-side frame are overlapped.

Abstract: In a rear vehicle-body structure of a vehicle provided with rear side frames, a first deformation promotion portion (recess portions) to promote inward deformation of the rear side frame is provided at each of both-side side face portions of the rear side frame, a second deformation promotion portion (opening portions) to promote outward deformation of the rear side frame is provided at a lower face portion of the rear side frame, and the first deformation promotion portion and the second deformation promotion portion are alternately arranged in an axial direction of the rear side frame.

Abstract: The present invention provides a compound of Formula I: for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R1, X1, R7, R5, C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.

Abstract: An engine stop control device is provided for a vehicle that ensures a sufficient operation frequency of coast stop operation during travel on a congested road, thereby to improve practical fuel economy. The vehicle has an engine that is capable of being restarted. A controller is configured to stop the engine automatically when the vehicle, after experiencing a travel with a vehicle speed VSP exceeding a first threshold value, decreases the speed below a CS (coast stop) start vehicle speed. The controller is further configured to set a second threshold value below the first threshold value. The controller is further configured, after starting from an engine automatic stop due to the coast stop control and when the vehicle experiences travel exceeding the second threshold value without exceeding the first threshold value, to permit the automatic engine stop due to the coast stop control at least once.

Abstract: A pair of rear side frames respectively comprise front bending-promotion portions, middle bending-promotion portions and rear bending-promotion portions which cause the rear side frames to bend inward, in a vehicle width direction, in a trough-folding shape in a rear collision of a vehicle, and a longitudinal distance L2 between the front bending-promotion portions and the middle bending-promotion portions is set to be longer than a longitudinal direction L1 between the middle bending-promotion portions and the rear bending-promotion portions. Thereby, there is provided a rear vehicle-body structure of an automotive vehicle which can properly absorb a collision load at a vehicle-body rear portion, even if a rear side frame is made from material which may not cause smooth bucking of the rear side frame.

Abstract: A pair of rear side frames respectively comprise front bending-promotion portions, middle bending-promotion portions and rear bending-promotion portions which cause the rear side frames to bend inward, in a vehicle width direction, in a trough-folding shape in a rear collision of a vehicle, and a longitudinal distance L2 between the front bending-promotion portions and the middle bending-promotion portions is set to be longer than a longitudinal direction L1 between the middle bending-promotion portions and the rear bending-promotion portions. Thereby, there is provided a rear vehicle-body structure of an automotive vehicle which can properly absorb a collision load at a vehicle-body rear portion, even if a rear side frame is made from material which may not cause smooth bucking of the rear side frame.

Abstract: The invention provides a soil improvement agent composition which contains (A) a fatty acid polyoxyalkylene alkyl ether represented by formula (1): R1CO (EO)m (PO)n OR2 (1) wherein R1 is a straight-chain or branched hydrocarbon group having 13 to 21 carbon atoms, EO represents ethylene oxide, m is a number of 2 to 10, PO represents propylene oxide, n is a number of 1 to 4, and R2 is a hydrocarbon group having 1 to 3 carbon atoms; and (B) a polyoxyalkylene alkyl ether represented by formula (2): R3O (EO)x (PO)y H (2) wherein R3 is a straight-chain or branched hydrocarbon group having 8 to 14 carbon atoms, EO represents ethylene oxide, x is a number of 7 to 12, PO represents propylene oxide, and y is a number of 0 to 3.

Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.

Abstract: Provided is a power management system capable of controlling charge and discharge of storage batteries according to power requirement of load even when handling electric power of large scale. A system controller receives load-related information data including the power requirement of load and storage battery-related information data including a state of a storage battery assembly including multiple storage batteries and creates an overall charge-discharge control instruction for the entire power management system based on the load-related information data and the storage battery-related information data. A hierarchical charge-discharge control apparatus receives the overall charge-discharge control instruction from the system controller and performs charge-discharge control of the multiple storage batteries, classified into hierarchical levels, on a hierarchical level basis.

Abstract: The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.